Dapsone Induced Methemoglobinemia Study (DIMS)
- Determine host-related risk factors for developing symptomatic methemoglobinemia in
patients with pediatric hematologic malignancies or aplastic anemia who received
dapsone prophylaxis for pneumocystis carinii.
- Determine whether a deficiency in cytochrome b5 reductase is a risk factor for
symptomatic methemoglobinemia in a subset of these patients.
- Collect a genomic DNA specimen from a subset of patients for whom enzyme testing is
being conducted to store for future analyses of variations in the genes responsible for
cytochrome b5 reductase.
OUTLINE: Patients' medical records are reviewed for possible risk factors (e.g., age, sex,
and body mass index) for developing symptomatic methemoglobinemia.
A subset of patients undergo blood sample collection for analysis of cytochrome b5 reductase
levels. DNA samples are also collected from these patients for future genetic polymorphism
Age, sex, and body mass index as host-related risk factors for developing symptomatic methemoglobinemia
Adam J. Esbenshade, MD
Vanderbilt-Ingram Cancer Center
United States: Federal Government
|Vanderbilt-Ingram Cancer Center||Nashville, Tennessee 37232-6838|
|Vanderbilt-Ingram Cancer Center - Cool Springs||Nashville, Tennessee 37064|